(Q35620305)

English

Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer's dementia: a pooled area under the curve analysis

scientific article published on 18 May 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 August 2017

Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer's dementia: a pooled area under the curve analysis (English)

1 reference

Europe PubMed Central

9 August 2017

Alzheimer's disease

0 references

1 reference

based on heuristic

inferred from title

José Luis Molinuevo

object named as

José Luis Molinuevo

6

0 references

author name string

Alireza Atri

1

1 reference

Europe PubMed Central

9 August 2017

Suzanne B Hendrix

2

1 reference

Europe PubMed Central

9 August 2017

Vojislav Pejović

3

1 reference

Europe PubMed Central

9 August 2017

Robert K Hofbauer

4

1 reference

Europe PubMed Central

9 August 2017

John Edwards

5

1 reference

Europe PubMed Central

9 August 2017

Stephen M Graham

7

1 reference

Europe PubMed Central

9 August 2017

language of work or name

0 references

publication date

18 May 2015

1 reference

Europe PubMed Central

9 August 2017

Alzheimers Research & Therapy

1 reference

Europe PubMed Central

9 August 2017

7

1 reference

Europe PubMed Central

9 August 2017

1

1 reference

Europe PubMed Central

9 August 2017

28

1 reference

Europe PubMed Central

9 August 2017

https://scigraph.springernature.com/pub.10.1186/s13195-015-0109-2

0 references

Rethinking the Food and Drug Administration's 2013 guidance on developing drugs for early-stage Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436119

12 July 2018

The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436119

12 July 2018

Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436119

12 July 2018

Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436119

12 July 2018

Validity, significance, strengths, limitations, and evidentiary value of real-world clinical data for combination therapy in Alzheimer's disease: comparison of efficacy and effectiveness studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436119

12 July 2018

An overview of longitudinal data analysis methods for neurological research

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436119

12 July 2018

Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436119

12 July 2018

Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436119

12 July 2018

Long-term course and effectiveness of combination therapy in Alzheimer disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436119

12 July 2018

Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436119

12 July 2018

Ecological validity in neuropsychological assessment: a case for greater consideration in research with neurologically intact populations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436119

12 July 2018

Memantine for dementia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436119

12 July 2018

Summary measures were a useful alternative for analyzing therapeutic clinical trial data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436119

12 July 2018

Cholinesterase inhibitors for Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436119

12 July 2018

Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436119

12 July 2018

A rationale for the use of summary measurements for the assessment of the effects of rheumatoid arthritis therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436119

12 July 2018

Natural history of Alzheimer's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436119

12 July 2018

The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436119

12 July 2018

An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436119

12 July 2018

Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436119

12 July 2018

The Neuropsychiatric Inventory: assessing psychopathology in dementia patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436119

12 July 2018

Analysis of serial measurements in medical research

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436119

12 July 2018

Regulation of drugs for early Alzheimer's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436119

25 September 2018

Longitudinal changes in functional disability in Alzheimer's disease patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436119

25 September 2018

Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436119

25 September 2018

A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436119

25 September 2018

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436119

25 September 2018

Memantine in moderate-to-severe Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436119

25 September 2018

Severe impairment battery. A neuropsychological test for severely demented patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4436119

25 September 2018

Effectiveness of antidementia drugs in delaying Alzheimer's disease progression.

1 reference

https://api.crossref.org/works/10.1186%2FS13195-015-0109-2

21 January 2018

Identifiers

10.1186/S13195-015-0109-2

1 reference

Europe PubMed Central

9 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35620305&oldid=1524708190"